Designing novel inhibitors against Mycobacterium tuberculosis FadA5 (acetyl-CoA acetyltransferase) by virtual screening of known anti-tuberculosis (bioactive) compounds.

ABSTRACT: By-products of fatty acid degradation are extensively utilized by Mycobacterium tuberculosis (Mtb) for lipid synthesis and energy production during the infection phase. Cholesterol from host is scavenged by Mtb to fulfill its metabolic requirements, evade host immunity and invade macrophages. Blocking cholesterol catabolic pathways leads to bacteriostasis. FadA5 (Acetyl-CoA acetyltransferase), a thiolase encoded by fadA5 (Rv3546) gene in Mtb, plays a crucial role in cholesterol aliphatic chain degradation. Hence, FadA5 is a potential target for designing antitubercular inhibitors. In this study, 60,284 anti-tuberculosis (bioactive) compounds from ChEMBL database and analogous library from ZINC database of commercially available compounds have been screened against FadA5 active site to identify compounds having inhibitory potential against both the apo (state I) and the intermediate (state II) states of FadA5. Altogether, this study reports 7 potential inhibitors against two functional states of FadA5, which can be further taken for invitro studies.

SUBMITTER: Jaiswal AK 

PROVIDER: S-EPMC6137569 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature